Lineage Cell Therapeutics, Inc.
LCTX
$1.27
$0.0958.12%
AMEX
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 84.09% | -47.63% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 84.09% | -47.63% | |||
| Cost of Revenue | 5.50% | -16.66% | |||
| Gross Profit | 74.31% | -108.60% | |||
| SG&A Expenses | -6.11% | 10.36% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -3.77% | 0.36% | |||
| Operating Income | 24.06% | -27.30% | |||
| Income Before Tax | -632.90% | -27.48% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -632.90% | -27.48% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -2,600.00% | 117.39% | |||
| Net Income | -636.02% | -26.46% | |||
| EBIT | 24.06% | -27.30% | |||
| EBITDA | 24.79% | -27.87% | |||
| EPS Basic | -628.96% | -34.56% | |||
| Normalized Basic EPS | -276.32% | -32.56% | |||
| EPS Diluted | -628.96% | -34.56% | |||
| Normalized Diluted EPS | -276.32% | -32.56% | |||
| Average Basic Shares Outstanding | 1.02% | -5.89% | |||
| Average Diluted Shares Outstanding | 1.02% | -5.89% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||